These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 4085525)

  • 1. Theoretical Michaelis-Menten elimination model for propranolol.
    McAinsh J; Gay MA
    Eur J Drug Metab Pharmacokinet; 1985; 10(3):241-5. PubMed ID: 4085525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability of sustained release propranolol formulations.
    McAinsh J; Baber NS; Holmes BF; Young J; Ellis SH
    Biopharm Drug Dispos; 1981; 2(1):39-48. PubMed ID: 7236870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of long-acting propranolol ('Inderal' LA) in the management of elderly hypertensive patients.
    Hamdy C; Tovey D; Baber NS; McAinsh J
    Eur J Clin Pharmacol; 1982; 22(5):379-81. PubMed ID: 7117349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic studies with a new controlled-release formulation of propranolol in normal volunteers: a comparison with other commercially available formulations.
    Perucca E; Grimaldi R; Gatti G; Caravaggi M; Crema F; Lecchini S; Frigo GM
    Br J Clin Pharmacol; 1984 Jul; 18(1):37-43. PubMed ID: 6743489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Propranolol: pooled Michaelis-Menten parameters and the effect of input rate on bioavailability.
    Wagner JG
    Clin Pharmacol Ther; 1985 May; 37(5):481-7. PubMed ID: 3987171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of acute alcohol administration on propranolol absorption.
    Grabowski BS; Cady WJ; Young WW; Emery JF
    Int J Clin Pharmacol Ther Toxicol; 1980 Jul; 18(7):317-9. PubMed ID: 7429677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug input rate from the GI-tract. Michaelis-Menten kinetics and the bioavailability of slow release verapamil and nifedipine.
    Woodcock BG; Menke G; Fischer A; Köhne H; Rietbrock N
    Drug Des Deliv; 1988 May; 2(4):299-310. PubMed ID: 3255321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Likely explanation for longer duration of pharmacological (antianginal) effects of propranolol in relation to its short half-life.
    Ishizaki T
    Res Commun Chem Pathol Pharmacol; 1980 Feb; 27(2):223-39. PubMed ID: 7367746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics and pharmacological actions of a long-acting formulation of propranolol.
    Ohashi K; Ebihara A; Kondo K; Usami M
    Arzneimittelforschung; 1984; 34(4):507-12. PubMed ID: 6378211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of propranolol during pregnancy.
    O'Hare MF; Kinney CD; Murnaghan GA; McDevitt DG
    Eur J Clin Pharmacol; 1984; 27(5):583-7. PubMed ID: 6519163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased absorption as a possible cause for the lower bioavailability of a sustained-release propranolol.
    Takahashi H; Ogata H; Warabioka R; Kashiwada K; Ohira M; Someya K
    J Pharm Sci; 1990 Mar; 79(3):212-5. PubMed ID: 2338628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of long acting propranolol. Implications for therapeutic use.
    Nace GS; Wood AJ
    Clin Pharmacokinet; 1987 Jul; 13(1):51-64. PubMed ID: 3304770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modification of propranolol's bioavailability by Eurycoma longifolia water-based extract.
    Salman SA; Amrah S; Wahab MS; Ismail Z; Ismail R; Yuen KH; Gan SH
    J Clin Pharm Ther; 2010 Dec; 35(6):691-6. PubMed ID: 21054461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the pharmacokinetics of propranolol in obese and normal volunteers.
    Bowman SL; Hudson SA; Simpson G; Munro JF; Clements JA
    Br J Clin Pharmacol; 1986 May; 21(5):529-32. PubMed ID: 3718810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Theoretical considerations in the calculation of bioavailability of drugs exhibiting Michaelis-Menten elimination kinetics.
    Rubin GM; Tozer TN
    J Pharmacokinet Biopharm; 1984 Aug; 12(4):437-50. PubMed ID: 6527233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies of the absorption and removal of propranolol in hypertensive patients during therapy.
    Chidsey CA; Morselli P; Bianchetti G; Morganti A; Leonetti G; Zanchetti A
    Circulation; 1975 Aug; 52(2):313-8. PubMed ID: 1149212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of propranolol: a review.
    Shand DG
    Postgrad Med J; 1976; 52 Suppl 4():22-25. PubMed ID: 787953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability of propranolol in the dog.
    Tse FL; Sanders TM; Reo JP
    Arch Int Pharmacodyn Ther; 1980 Dec; 248(2):180-9. PubMed ID: 7224706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.
    Johnsson G; Regàrdh CG
    Clin Pharmacokinet; 1976; 1(4):233-63. PubMed ID: 13958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic study of a new sustained release preparation of propranolol in normal healthy volunteers.
    Biswas NR; Garg SK; Lal R; Kumar N; Gyawali K; Narendranath KA; Sharma PL
    Int J Clin Pharmacol Ther Toxicol; 1988 Sep; 26(9):436-8. PubMed ID: 3198297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.